‘Game-changing’ immunotherapy doubles head and neck cancer survival
An immunotherapy drug has been hailed as a potential ‘game changer’ after being found to greatly improve survival for patients with relapsed head and neck cancer – a disease which is notoriously difficult to treat.
Nivolumab became the first treatment to extend survival in a phase III clinical trial for patients with head and neck cancer in whom chemotherapy had failed – and it did so with fewer side-effects than existing therapeutic options.
Click on this link for more information.
